Showing results (1-10 of 6) with videos related to
Sort By:
Pageof 1
Current Drug Targets|June 20, 2017
Targeting Cholinergic System to Modulate Liver InjuryRavirajsinh N Jadeja, Vikrant P Rachakonda, Sandeep KhuranaHepatology Communications|October 7, 2020
Differential Outcomes and Clinical Challenges of NAFLD With Extreme ObesityJoud Arnouk, Vikrant P Rachakonda, Diana Jaiyeola, et al.American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|October 17, 2014
Unusually late-onset mycophenolate mofetil-related colitisBryan F Curtin, Vikrant P Rachakonda, Erik C Von RosenvingeHepatology Communications|October 9, 2019
Impact of Hepatic Steatosis on Resting Metabolic Rate and Metabolic Adaptation in Response to Intentional Weight LossVikrant P Rachakonda, James P DeLany, Erin E Kershaw, et al.Plos One|November 27, 2019
The ZJU index is a powerful surrogate marker for NAFLD in severely obese North American womenChia-Po Fu, Hira Ali, Vikrant P Rachakonda, et al.Obesity (Silver Spring, Md.)|April 14, 2015
Serum autotaxin is independently associated with hepatic steatosis in women with severe obesityVikrant P Rachakonda, Valerie L Reeves, Jules Aljammal, et al.Pageof 1